Previous 10 | Next 10 |
home / stock / esaly / esaly news
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight. The o...
Delmaine Donson/E+ via Getty Images If this morning's announcement from Bristol-Myers Squibb (BMY) for up to $3B for development and commercialization of Eisai's (ESALY) MORAb-202 antibody drug conjugate sounds familiar, you're right. Back in March 2019, AstraZeneca (AZN) and Daiichi San...
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate Tokyo and New York, June 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered...
Volodymyr Horbovyy/iStock via Getty Images Shares of Anavex Life Sciences (AVXL)are down more than 17% in morning trading, a day after the stock closed up 35%. The stock shot up yesterday after details on the mechanism of action of two of its Alzheimer's disease candidates, ANAVEX2-...
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma TOKYO, June 15, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) i...
Eisai Receives Special Prize at Platinum Career Award 2021 TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021. ...
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021) TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist le...
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM Cambridge, MA, June 8, 2021 - (JCN Newswire) - Following U.S. Food and Drug Administration's (FDA) accelerated approval of ADUHELMTM (aducanumab-avwa) as the first and only Alzheimer's...
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease TOKYO, June 8, 2021 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food an...
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib TOKYO and KENILWORTH, N.J., June 8, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CL...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...